))
Deep Dive 206 – Intellectual Property in a Pandemic: The Proposed COVID-19 WTO Waiver
Manage episode 317395374 series 3276400
内容由The Federalist Society提供。所有播客内容（包括剧集、图形和播客描述）均由 The Federalist Society 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
In October 2020, India and South Africa filed a request at the World Trade Organization (WTO) to create an exemption from an international treaty known as TRIPS (Trade-Related aspects of Intellectual Property Rights) for technologies, drugs, and vaccines used to respond to the COVID-19 pandemic. If the WTO adopts the waiver, countries could refuse to issue and protect IP rights for those technologies.
Some argue that the waiver is a necessary measure that would give a boost to the global fight against COVID-19, but others contend it would do little to help defeat the current pandemic and could hinder future innovation. An expert panel joined us to discuss the proposed waiver and weigh the arguments on each side of the debate.
In October, members of RTP's Intellectual Property Working Group published a white paper on the same topic, which you can read here:
https://regproject.org/paper/covid-vaccine-ip-waiver-a-pathway-to-fewer-not-more-vaccines/
Featuring:
- Andrei Iancu, Partner, Irell & Manella LLP
- David Kappos, Partner, Cravath Swaine & Moore LLP
- Arti Rai, Elvin R. Latty Professor of Law, Duke University School of Law
- [Moderator] Saurabh Vishnubhakat, Professor of Law, Texas A&M University School of Law
Visit our website – www.RegProject.org – to learn more, view all of our content, and connect with us on social media.
…
continue reading
Some argue that the waiver is a necessary measure that would give a boost to the global fight against COVID-19, but others contend it would do little to help defeat the current pandemic and could hinder future innovation. An expert panel joined us to discuss the proposed waiver and weigh the arguments on each side of the debate.
In October, members of RTP's Intellectual Property Working Group published a white paper on the same topic, which you can read here:
https://regproject.org/paper/covid-vaccine-ip-waiver-a-pathway-to-fewer-not-more-vaccines/
Featuring:
- Andrei Iancu, Partner, Irell & Manella LLP
- David Kappos, Partner, Cravath Swaine & Moore LLP
- Arti Rai, Elvin R. Latty Professor of Law, Duke University School of Law
- [Moderator] Saurabh Vishnubhakat, Professor of Law, Texas A&M University School of Law
Visit our website – www.RegProject.org – to learn more, view all of our content, and connect with us on social media.
374集单集
分享
